Literature DB >> 2396741

Simple and unambiguous method for identifying urinary acylcarnitines using gas chromatography--mass spectrometry.

S Lowes1, M E Rose.   

Abstract

Several inherited metabolic disorders, particularly the organic acidurias and acidemias, are often characterised by excretion of acylcarnitines, especially octanoylcarnitine, in the urine. Clinical investigation of such serious disorders ideally requires a rapid, simple and selective method for determining acylcarnitines in urine. Initial results are given here of a method that may approach this ideal. The procedure involves chemical derivatisation, in which the zwitterionic acylcarnitines are cyclised to volatile lactones, and analysis by gas chromatography and gas chromatography--mass spectrometry. Preparation of urine samples by ion-exchange purification and an illustrative application of the proposed method to a clinical sample are also outlined.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2396741     DOI: 10.1039/an9901500511

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  6 in total

Review 1.  Acylcarnitines in intermediary metabolism.

Authors:  A C Sewell; H J Böhles
Journal:  Eur J Pediatr       Date:  1995-11       Impact factor: 3.183

2.  Picolinyl ester fragmentation mechanism studies with application to the identification of acylcarnitine acyl groups following transesterification.

Authors:  Shuming Yang; Paul Minkler; Charles Hoppel; Kou-Yi Tserng
Journal:  J Am Soc Mass Spectrom       Date:  2006-08-09       Impact factor: 3.109

3.  Identification of new medium-chain acylcarnitines present in urine of a patient with medium-chain acyl-CoA dehydrogenase deficiency.

Authors:  R Libert; F Van Hoof; M Thillaye; M F Vincent; M C Nassogne; V Stroobant; E de Hoffmann; A Schanck
Journal:  J Inherit Metab Dis       Date:  1999-02       Impact factor: 4.982

4.  Acylcarnitine profile in tissues and body fluids of biotin-deficient rats with and without L-carnitine supplementation.

Authors:  Y Shigematsu; I L Bykov; Y Y Liu; A Nakai; Y Kikawa; M Sudo; M Fujioka
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

5.  Stroke, hemiparesis and deficient mitochondrial beta-oxidation.

Authors:  L Vallée; M Fontaine; J P Nuyts; G Ricart; I Krivosic; P Divry; C Vianey-Saban; M Lhermitte; J Vamecq
Journal:  Eur J Pediatr       Date:  1994-08       Impact factor: 3.183

Review 6.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.